Business
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
NEW YORK, January 12, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI® (taletrectinib) and provided a 2026 outlook ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":17689,"height":2887,"url":"https://media.zenfs.com/en/business-wire.com/3249e8e90478a839a662dc3e43c629a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qRmiLvThm4MPUr0GEWZE.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3249e8e90478a839a662dc3e43c629a5","width":960,"height":157},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VzDgzlcnb.VyHa54JogMxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zOTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3249e8e90478a839a662dc3e43c629a5","width":1200,"height":196}},"lazy":false},{"type":"text","content":"Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"Preliminary IBTROZI net product revenue of approximately $15.7 million in the fourth quarter and $24.7 million since launch","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"Preliminary unaudited cash, cash equivalents and marketable securities of approximately $529.2 million as of December 31, 2025","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"Company to present at 44th Annual J.P. Morgan Healthcare Conference tomorrow, January 13, at 3:45 p.m. PT/6:45 p.m. ET","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, January 12, 2026--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI® (taletrectinib) and provided a 2026 outlook ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.","length":415,"tagName":"p"},{"type":"text","content":"Preliminary Fourth Quarter and Full Year 2025 Financial Results and IBTROZI Commercial Results","length":94,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the third quarter, the company’s first full quarter of sales, 204 new patients started treatment on IBTROZI for advanced ROS1-positive (ROS1+) non-smal...